{
    "clinical_study": {
        "@rank": "40394", 
        "brief_summary": {
            "textblock": "To provide ganciclovir on a compassionate use basis to immunocompromised patients with\n      serious cytomegalovirus (CMV) infections and to study safety and efficacy in this patient\n      population."
        }, 
        "brief_title": "Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections", 
        "condition": [
            "Cytomegalovirus Infections", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Cytomegalovirus Infections"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Topical acyclovir.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following are excluded:\n\n          -  Mild to moderate cytomegalovirus (CMV) infections that fail to satisfy the clinical\n             severity criteria.\n\n          -  Transplant where a trial reduction of immunosuppressive drug treatment is not\n             feasible.\n\n          -  Congenital or neonatal CMV infections where there is not documented congenital or\n             acquired immunodeficiency.\n\n          -  Neutropenia unless it is pre-existing.\n\n          -  Thrombocytopenia unless it is pre-existing.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Other myelosuppressive drugs such as cancer chemotherapy agents, interferon,\n             foscarnet, or nucleoside analogs.\n\n        Patients with the following are excluded:\n\n          -  Mild to moderate cytomegalovirus (CMV) infections that fail to satisfy the clinical\n             severity criteria.\n\n          -  Transplant where a trial reduction of immunosuppressive drug treatment is not\n             feasible.\n\n          -  Congenital or neonatal CMV infections where there is not documented congenital or\n             acquired immunodeficiency.\n\n          -  Neutropenia unless it is pre-existing.\n\n          -  Thrombocytopenia unless it is pre-existing.\n\n        Patients must be immunocompromised with a serious cytomegalovirus (CMV) infection. This\n        would include pneumonia, gastrointestinal disease, hepatitis, or other organ-specific\n        disease or severe wasting syndrome. Patients with pre-existing neutropenia or\n        thrombocytopenia, and immediate life-threatening disease can be included if the\n        investigator believes that delay in starting ganciclovir therapy is not advisable. In such\n        patients, the investigator must advise the patient of the risk of further marrow\n        suppression and the increased risk of infection or bleeding; and the patient must sign an\n        amended informed consent form."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002024", 
            "org_study_id": "029B", 
            "secondary_id": "ICM 1257A"
        }, 
        "intervention": {
            "intervention_name": "Ganciclovir", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Ganciclovir"
        }, 
        "keyword": [
            "AIDS-Related Opportunistic Infections", 
            "Immune Tolerance", 
            "Ganciclovir", 
            "Drugs, Investigational", 
            "Cytomegalovirus Infections", 
            "Acquired Immunodeficiency Syndrome"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Palo Alto", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94303"
                }, 
                "name": "Roche Global Development - Palo Alto"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": {
            "PMID": "8618603", 
            "citation": "Spector SA, McKinley GF, Lalezari JP, Samo T, Andruczk R, Follansbee S, Sparti PD, Havlir DV, Simpson G, Buhles W, Wong R, Stempien M. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med. 1996 Jun 6;334(23):1491-7."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002024"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 1989"
    }, 
    "geocoordinates": {
        "Roche Global Development - Palo Alto": "37.442 -122.143"
    }
}